131 related articles for article (PubMed ID: 35661156)
1. Grading bloodstream infection risk using citrulline as a biomarker of intestinal mucositis in patients receiving intensive therapy.
de Mooij CEM; van der Velden WJFM; de Haan AFJ; Fazel S; van Groningen LFJ; Blijlevens NMA
Bone Marrow Transplant; 2022 Sep; 57(9):1373-1381. PubMed ID: 35661156
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
[TBL] [Abstract][Full Text] [Related]
3. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
Dandoy CE; Kim S; Chen M; Ahn KW; Ardura MI; Brown V; Chhabra S; Diaz MA; Dvorak C; Farhadfar N; Flagg A; Ganguly S; Hale GA; Hashmi SK; Hematti P; Martino R; Nishihori T; Nusrat R; Olsson RF; Rotz SJ; Sung AD; Perales MA; Lindemans CA; Komanduri KV; Riches ML
JAMA Netw Open; 2020 Jan; 3(1):e1918668. PubMed ID: 31913492
[TBL] [Abstract][Full Text] [Related]
4. Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013.
Epstein L; See I; Edwards JR; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2016 Jan; 37(1):2-7. PubMed ID: 26456954
[TBL] [Abstract][Full Text] [Related]
5. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan.
Kato Y; Hagihara M; Kurumiya A; Takahashi T; Sakata M; Shibata Y; Kato H; Shiota A; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2018 Jan; 24(1):31-35. PubMed ID: 29066217
[TBL] [Abstract][Full Text] [Related]
6. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition.
See I; Iwamoto M; Allen-Bridson K; Horan T; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2013 Aug; 34(8):769-76. PubMed ID: 23838215
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal Barrier Injury.
Balian C; Garcia M; Ward J
J Pediatr Oncol Nurs; 2018 May; 35(3):210-217. PubMed ID: 29560765
[TBL] [Abstract][Full Text] [Related]
8. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.
Herbers AH; de Haan AF; van der Velden WJ; Donnelly JP; Blijlevens NM
Transpl Infect Dis; 2014 Apr; 16(2):279-85. PubMed ID: 24621081
[TBL] [Abstract][Full Text] [Related]
9. The applicability of the central line-associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients.
van den Bosch CH; Frakking FNJ; Loeffen YGT; van Tinteren H; van der Steeg AFW; Wijnen MHWA; van de Wetering MD; van der Bruggen JT
Eur J Haematol; 2024 May; 112(5):832-839. PubMed ID: 38294085
[TBL] [Abstract][Full Text] [Related]
10. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.
Metzger KE; Rucker Y; Callaghan M; Churchill M; Jovanovic BD; Zembower TR; Bolon MK
Infect Control Hosp Epidemiol; 2015 Feb; 36(2):119-24. PubMed ID: 25632993
[TBL] [Abstract][Full Text] [Related]
11. Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation.
Giri VK; Kegerreis KG; Ren Y; Bohannon LM; Lobaugh-Jin E; Messina JA; Matthews A; Mowery YM; Sito E; Lassiter M; Saullo JL; Jung SH; Ma L; Greenberg M; Andermann TM; van den Brink MRM; Peled JU; Gomes ALC; Choi T; Gasparetto CJ; Horwitz ME; Long GD; Lopez RD; Rizzieri DA; Sarantopoulos S; Chao NJ; Allen DH; Sung AD
Transplant Cell Ther; 2021 Mar; 27(3):262.e1-262.e11. PubMed ID: 33781532
[TBL] [Abstract][Full Text] [Related]
12. A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients.
Gaur AH; Bundy DG; Werner EJ; Hord JD; Miller MR; Tang L; Lawlor JP; Billett AL;
Infect Control Hosp Epidemiol; 2017 Jun; 38(6):690-696. PubMed ID: 28399945
[TBL] [Abstract][Full Text] [Related]
13. Association between parenteral nutrition-containing intravenous lipid emulsion and bloodstream infections in patients with single-lumen central venous access: A secondary analysis of a randomized trial.
Gavin NC; Larsen E; Runnegar N; Mihala G; Keogh S; McMillan D; Ray-Barruel G; Rickard CM
JPEN J Parenter Enteral Nutr; 2023 Aug; 47(6):783-795. PubMed ID: 37288612
[TBL] [Abstract][Full Text] [Related]
14. The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.
Torres D; González ML; Loera A; Aguilera M; Relyea G; Aristizabal P; Caniza MA
Am J Infect Control; 2016 Apr; 44(4):432-7. PubMed ID: 26775931
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient.
Eduardo FP; Bezinelli LM; Gobbi M; Rosin FCP; Carvalho DLC; Ferreira MH; da Silva CC; Hamerschlak N; Corrêa L
Support Care Cancer; 2019 Mar; 27(3):839-848. PubMed ID: 30109488
[TBL] [Abstract][Full Text] [Related]
16. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients.
Gudiol C; Garcia-Vidal C; Arnan M; Sánchez-Ortega I; Patiño B; Duarte R; Carratalà J
Bone Marrow Transplant; 2014 Jun; 49(6):824-30. PubMed ID: 24662420
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of bloodstream infections after myeloablative and non-myeloablative allogeneic hematopoietic stem cell transplantation: A single-center cohort study.
Gjaerde LI; Moser C; Sengeløv H
Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28561378
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of central line salvage for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) management practices in patients with hematologic malignancies.
El Boghdadly Z; Zhao Q; Koutou J; Lustberg ME; Ludwig M; Liscynesky C; Choe H
Leuk Lymphoma; 2022 Jun; 63(6):1455-1463. PubMed ID: 35001802
[TBL] [Abstract][Full Text] [Related]
19. Oral microorganisms and bloodstream infection in allogeneic hematopoietic stem cell transplantation.
Ohbayashi Y; Imataki O; Uemura M; Takeuchi A; Aoki S; Tanaka M; Nakai Y; Nakai F; Miyake M
Clin Oral Investig; 2021 Jul; 25(7):4359-4367. PubMed ID: 33392808
[TBL] [Abstract][Full Text] [Related]
20. Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.
Facchini L; Martino R; Ferrari A; Piñana JL; Valcárcel D; Barba P; Granell M; Delgado J; Briones J; Sureda A; Brunet S; Sierra J
Eur J Haematol; 2012 Jan; 88(1):46-51. PubMed ID: 22023368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
